TY - JOUR
T1 - The Adult ADHD Quality Measures Initiative
AU - Faraone, Stephen V.
AU - Silverstein, Michael J.
AU - Antshel, Kevin
AU - Biederman, Joseph
AU - Goodman, David W.
AU - Mason, Oren
AU - Nierenberg, Andrew A.
AU - Rostain, Anthony
AU - Stein, Mark A.
AU - Adler, Lenard A.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by unrestricted educational and research grants from the following pharmaceutical companies: Arbor, Otsuka, Shire, and Sunovion.
Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support, and/or research support from Otsuka, Arbor, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Ironshore, Sunovion, Supernus, and Genomind. With his institution, he has U.S. patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In the past year, Dr. Stein received income, travel expenses, and/or research support from Akili Interactive Labs, Neos, NLS, Pfizer, Shire, Sunovion, Supernus, and Genomind. In the past year, Dr. Goodman received honoraria, travel expenses, continuing education support, from Shire, Ironshore, Sunovion, Supernus, NLS Pharma, Otsuka, Arbor, Guidepoint Global, Acakat, Slingshot Insights, Primary Insight LLC, and Pontifax. In the past year, Dr. Antshel received research funding from Shire Pharmaceutical Company. In the past year, Dr. Mason received income and travel expenses from Sunovion and Arbor. In the past year, Dr. Rostain received honoraria, travel expenses, and continuing education support from Shire, Ironshore, Arbor, and the National Football League. He also received royalties from Routledge/Taylor Francis Group and St. Martin’s Press. In the past year, Dr. Nierenberg received potential income, travel expenses continuing education support, and/or research support from Alkermes, APARD, Assurex, Guildford Publications, Janssen, Jazz, Neurocrine, NeuroRx, Otsuka, Sage, Shire, Slack Inc, Sunovion, Supernus, Takeda, and UpToDate. Dr. Joseph Biederman is currently receiving research support from the following sources: AACAP, Feinstein Institute for Medical Research, Food & Drug Administration, Headspace Inc., Lundbeck AS, Neurocentria Inc., NIDA, Pfizer Pharmaceuticals, Roche TCRC Inc., Shire Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., and NIH. Dr. Biederman has a financial interest in Avekshan LLC, a company that develops treatments for ADHD. His interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr. Biederman’s program has received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. In 2018, Dr. Biederman is on the scientific advisory board for Akili and Shire. Through MGH corporate licensing, he has a U.S. Patent (#14/027,676) for a nonstimulant treatment for ADHD, and a patent pending (#61/233,686) on a method to prevent stimulant abuse. In 2017, Dr. Biederman received research support from the Department of Defense and PamLab. He was a consultant for Aevi Genomics, Akili, Guidepoint, Ironshore, Medgenics, and Piper Jaffray. He was on the scientific advisory board for Alcobra and Shire. He received honoraria from the MGH Psychiatry Academy for tuition-funded CME courses. Dr Adler’s disclosures are as follows: Research: Enzymotec, Sunovion Pharmaceuticals, Shire Pharmaceuticals, Lundbeck. Consultant and/or Advisory Board: Sunovion Pharmaceuticals, Enzymotec, Shire Pharmaceuticals, Otsuka Pharmaceuticals, Bracket, SUNY, NFL, Major League Baseball. Royalties: Received royalty payments (as inventor) from NYU for the license of adult ADHD scales and training materials since 2004.
Publisher Copyright:
© The Author(s) 2018.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Objective: Quality measures (QMs; also known as Quality Indicators) quantify health care processes, outcomes, patient perceptions, and organizational structure and/or systems that are relevant to the provision of high-quality health care. We describe the first phase of a project that has as its ultimate goal the creation and validation of QMs for tracking the screening, diagnosis, treatment, and clinical follow-up of adults with ADHD. This will fill an important gap in the field of Adult ADHD because QMs for adult ADHD do not exist. Method: We followed the guidelines of the U.S. Agency for Healthcare Research and Quality (AHRQ) for the development of QMs. These guidelines call for two phases: (1) Identify Candidate QMs and (2) Assess Candidate QMs. This article describes the results of our Phase 1 activities. To generate QMs for adult ADHD, we took the following steps: (a) searched the clinical/research literature for adult ADHD QMs; (b) convened a multidisciplinary panel comprising clinical and research experts and had them brainstorm potential QMs in the areas of screening, diagnosis, treatment, follow-up, care coordination, and patient experience; (c) compared these QMs with existing guidelines for adult ADHD to see if any potential QMs had been missed, this led to a draft list of 46 QMs; (d) had 28 ADHD experts rate the importance, reliability, validity, feasibility, and usability of the QMs. Results: The literature review found several QMs for ADHD in youth but none for ADHD in adults. The brainstorming session generated 52 QMs. The survey showed that all of these QMs were highly rated but that there was sufficient variability in ratings to prioritize some QMs over others. Conclusion: Based on these results, we prioritized QMs to carry forward into the next phase of the project. This work fills an important gap for the clinical care of adult patients with ADHD and helps to set a precedent for mental health, which has lagged behind other areas of medicine in developing QMs.
AB - Objective: Quality measures (QMs; also known as Quality Indicators) quantify health care processes, outcomes, patient perceptions, and organizational structure and/or systems that are relevant to the provision of high-quality health care. We describe the first phase of a project that has as its ultimate goal the creation and validation of QMs for tracking the screening, diagnosis, treatment, and clinical follow-up of adults with ADHD. This will fill an important gap in the field of Adult ADHD because QMs for adult ADHD do not exist. Method: We followed the guidelines of the U.S. Agency for Healthcare Research and Quality (AHRQ) for the development of QMs. These guidelines call for two phases: (1) Identify Candidate QMs and (2) Assess Candidate QMs. This article describes the results of our Phase 1 activities. To generate QMs for adult ADHD, we took the following steps: (a) searched the clinical/research literature for adult ADHD QMs; (b) convened a multidisciplinary panel comprising clinical and research experts and had them brainstorm potential QMs in the areas of screening, diagnosis, treatment, follow-up, care coordination, and patient experience; (c) compared these QMs with existing guidelines for adult ADHD to see if any potential QMs had been missed, this led to a draft list of 46 QMs; (d) had 28 ADHD experts rate the importance, reliability, validity, feasibility, and usability of the QMs. Results: The literature review found several QMs for ADHD in youth but none for ADHD in adults. The brainstorming session generated 52 QMs. The survey showed that all of these QMs were highly rated but that there was sufficient variability in ratings to prioritize some QMs over others. Conclusion: Based on these results, we prioritized QMs to carry forward into the next phase of the project. This work fills an important gap for the clinical care of adult patients with ADHD and helps to set a precedent for mental health, which has lagged behind other areas of medicine in developing QMs.
KW - ADD/ADHD
KW - ADHD
KW - adult ADHD
KW - adult ADHD treatment
UR - http://www.scopus.com/inward/record.url?scp=85059537635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059537635&partnerID=8YFLogxK
U2 - 10.1177/1087054718804354
DO - 10.1177/1087054718804354
M3 - Review article
C2 - 30511593
AN - SCOPUS:85059537635
SN - 1087-0547
VL - 23
SP - 1063
EP - 1078
JO - Journal of Attention Disorders
JF - Journal of Attention Disorders
IS - 10
ER -